Replies to post #89231 on Creative Medical Technology Holdings Inc (CELZ)

[ramalio]

May be a solution: They simply are crooks!?

[Doubledown75]

If we had the ability to borrow shares to sell short and cover on a daily basis, thus no failure to deliver, we all could be market makers lol.
Reason there is no proof. They call it providing liquidity.
Reason we all try in the otc is they can be wrong:)

[docprep]

Um...because of the buyout

[justdafactss]

uva- 70. Intrexon acquired the ERC technology by purchasing failed microcap company Medistem, Inc. for $26 million in March 2014. The acquisition was announced in a press release on December 20, 2013. According to Medistem’s last filed Form 10-Q, dated November 12, 2013, it had a mere $10,000 in revenue and $274,637 of research and development in the first nine months of 2013and zero revenue and $418,594 of research and development the first nine months of 2012.

71. Medistem was controlled by Neil Riordan, who was a majority shareholder, President,CEO, and Chairman of the Board. Mr. Riordan has a questionable history. He claims to have a Ph.D from the Medical University of the Americas in St. Kitts and Nevis. He controlled multiple offshore stem cell clinics, which are widely acknowledged to be scams. His clinic in Costa Rica was shuttered by the government in 2010 because there was zero proof that its treatments were effective. This clinic was Medistem’s first licensee. Medistem’s Chief Scientific Officer, and later President and CEO, was Thomas Ichim, who claimed to have a Ph.D from the University of Science, Arts and Technology in Montserrat.

72. The value of Medistem’s ERC technology is dubious. All three papers about ERC listed on Intrexon’s website were co-authored by Riordan and Ichim. In a press release dated November 15, 2007, Medistem announced that it had co-discovered ERC and that the research was led by Dr. Xiaolong Meng of the Bio-Communications Research Institute. This institute, which no longer has a website, is located at the same Wichita, Kansas, address as one of Riordan’s clinics. According to Spotlight’s research, Dr. Xiaolong Meng is currently listed as an employee of the BioCommunications Research Institute, the Riordan Clinic Research Institute, and a Chinese herb dispensary in Australia.

http://securities.stanford.edu/filings-documents/1057/IC00_03/2016922_r01c_16CV02398.pdf